Evidence map›Paper›PMID 41179294›Full record

ArticleOncology research2025

Multi-Omics Insights into the Impact of MDH2 on Breast Cancer Progression: A Promising Druggable Target.

Botao Pan, Zirun Luo, Xiujuan Yang, Qingqing Liu, Zhimin Yang, Chenglai Xia

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Botao PanScientific Research Center, The Affiliated Foshan Women and Children Hospital, Guangdong Medical University, Foshan, 528000, China.
Zirun LuoDepartment of Breast, Thyroid and Head-Neck Surgery, Third Xiangya Hospital of Central South University, Changsha, 410000, China.
Xiujuan YangScientific Research Center, The Affiliated Foshan Women and Children Hospital, Guangdong Medical University, Foshan, 528000, China.
Qingqing LiuSchool of Pharmaceutical Sciences, Southern Medical University, Guangzhou, 515150, China.
Zhimin YangJiangsu Natural Active Pharmaceutical Ingredient Design and Separation Technology Engineering Research Center, School of Pharmaceutical Engineering, Jiangsu Food & Pharmaceutical Science College, Huai'an, 223003, China.
Chenglai XiaScientific Research Center, The Affiliated Foshan Women and Children Hospital, Guangdong Medical University, Foshan, 528000, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objectives: Breast cancer is characterized by significant metabolic dysregulation, in which altered enzyme activity plays a central role. Malate dehydrogenase 2 (MDH2), a key enzyme in the tricarboxylic acid cycle, has been implicated in several malignancies, but its role in breast cancer tumorigenesis and progression remains unclear. We aimed to elucidate the oncogenic role of MDH2 in breast cancer and to evaluate its potential as a diagnostic, therapeutic, and prognostic biomarker. Methods: We combined Results: Conclusion: Our findings highlight the role of MDH2 in breast cancer metabolism and suggest it as a promising target for cancer therapies targeting metabolism and tumor growth.

Indexed as

Breast NeoplasmsMalate DehydrogenaseAnimalsBiomarkers, TumorCell Line, TumorCell MovementCell ProliferationDisease ProgressionEpithelial-Mesenchymal TransitionFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansMetabolomicsMiceMultiomicsBiomarkers, TumorMalate DehydrogenaseBreast cancercancer metabolismdruggable targetimmunomodulatory metabolitesmalate dehydrogenase 2 (MDH2)

Identifiers

PMID41179294
PMCPMC12573209

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.